Tuberculosis multidrogorresistente
Multidrug-resistant tuberculosis
Tuberculose multirresistente
Rev. salud bosque; 10 (1), 2020
Publication year: 2020
La tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos antituberculosos), tiene una relevancia particular: de los 10 millones de personas que desarrollan TB anualmente, 458.000 presentan TB-MDR con un pronóstico mucho peor que el de los infectados por cepas sensibles. En el presente artículo se exploran los principales aspectos de la TB-MDR, haciendo énfasis en su tratamiento
Tuberculosis (TB) is the worldwide leading infectious cause of death and, the emergence of drug-resistant tuberculosis can only worsen the scenario. Multidrug-Resistant Tuberculosis (TB-MDR) has proven resistant to both isoniazid and rifampin, the main antituberculous drugs. Out of 10 million people developing TB annually, 458 000 exhibit TB-MDR, having worse prognosis than those infected by sensitive strains. Recently, new drug-resistant TB treatment guidelines were issued both by the World Health Organization and health authorities in Colombia. The present paper explores the main aspects of TB-MDR emphasizing s sanitary authorities also, new guidelines were published by Colombian minister of health and social protection. In this paper, the main aspects of TB-MDR are explored, especially those related to its treatment.